Treatment effects of EGb 761® and cholinesterase inhibitors - Why available studies do not demonstrate superiority of the latter

Phytomedicine

Volumn 12, Issue 8, 2005, Pages 598-600

  Hoerr, R ^a  

^a DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Efficacy; EGb 761; Ginkgo biloba

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; NOOTROPIC AGENT; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; GINKGO BILOBA; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS;

GINKGO BILOBA;

EID: 21744450577     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2004.06.020     Document Type: Article

References (16)

1. Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H.J., Rogers, S.L., Friedhoff, L.T., The International Donepezil Study Group, 1999. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord. 10, 237-244.
2. H.C. Chui, S.A. Lyness, E. Sobel, and L.S. Schneider Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease Arch. Neurol. 51 1994 676 681
3. Corey-Bloom, J., Anand, R., Veach, J., for the ENA 713 B352 Study Group, 1998. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. 1, 55-65.
4. E. Helmes, H. Merskey, H. Fox, R.N. Fry, J.V. Bowler, and V.C. Hachinski Patterns of deterioration in senile dementia of the Alzheimer type Arch. Neurol. 52 1995 306 310
5. Homma, A., Takeda, M., Imai, Y., Udaka, F., Hasegawa, K., Kameyama, M., Nishimura, T., E2020 Study Group, 2000. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dement. Geriatr. Cogn. Disord. 11, 299-313
6. A. Kurz, and B. Van Baelen Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the Cochrane Collaboration Dement. Geriatr. Cogn. Disord. 18 2004 217 226
7. P.L. Le Bars, M. Kieser, and K.Z. Itil A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia Dement. Geriatr. Cogn. Disord. 11 2000 230 237
8. O.L. Lopez, S.R. Wisniewski, J.T. Becker, F. Boller, and S.T. DeKosky Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease Arch. Neurol. 56 1999 1266 1272
9. J.A. Mortimer, B.E. Ebbitt, S.P. Jun, and M.D. Finch Predictors of cognitive and functional progression in patients with probable Alzheimer's disease Neurology 42 1992 1689 1696
10. Raskind, M.A., Peskind, E.R., Wessel, T., Yuan, W., The Galantamine USA-1 Study Group, 2000. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54, 2261-2268.
11. Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R., Friedhoff, L.T., The Donepezil Study Group, 1998. A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50, 136-145.
12. Rösler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stähelin, H.B., Hartman, R., Gharabawi, M., on behalf of the B303 Exelon Study Group, 1999. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. J. 318, 633-640.
13. R.G. Stern, R.C. Mohs, M. Davidson, J. Schmeidler, J. Silverman, E. Kramer-Ginsberg, T. Searcey, L. Bierer, and K.L. Davis A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration Am. J. Psychiat. 151 1994 390 396
14. Tariot, P.N., Solomon, P.R., Morris, J.C., Kershaw, P., Lilienfeld, S., Ding, C., The Galantamine USA-10 Study Group, 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54, 2269-2276.
15. A. Wettstein Cholinesterase inhibitors and Ginkgo extracts - are they comparable in the treatment of dementia? Phytomedicine 6 2000 393 401
16. Wilcock, G.K., Lilienfeld, S., Gaens, E., on behalf of the Galantamine International-1 Study Group, 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Br. Med. J. 321, 1445-1449.